FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA

Part of paid clinical trials in Coral Gables, Florida.

Sponsor
AAADRS Clinical Research Center
Study ID
NCT06437171
Phase
PHASE4
Status
Active Not Recruiting

Conditions

  • Food Allergy

Eligibility Criteria

Sex
ALL
Age
6 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Omalizumab — BIOLOGICAL
    Omalizumab dose and frequency based on baseline subject weight and total IgE

Study Details

This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.

Key Dates

Start date
Jun 3, 2024
Status verified
Aug 2025
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Open Label Injection of Omalizumab
    Omalizumab dose and frequency based on baseline patient weight and total IgE

Primary Outcome Measure

FeNO change from baseline to week 52 [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
AAADRS Clinical Research CenterCoral GablesFlorida33134-

Find similar trials in Coral Gables, FL

By research site
AAADRS Clinical Research Center· Coral Gables, FL

Related Studies